个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
C. Zhou[1] ; Z. Wang[2] ; Y. Sun[3] ; L. Cao[4] ; Z. Ma[5] ; R. Wu[6] ; Y. Yu[7] ; W. Yao[8] ; J. Chang[9] ; J. Chen[10] ; W. Zhuang[11] ; J. Cui[12] ; X. Chen[13] ; Y. Lu[14] ; H. Shen[15] ; P. Li[16] ; J. Wang[16] ; B. Sun[16] ; D. Lu[16] ; J. Yang[16] ;
机构： [1]Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN [2]The Department Of Respiratory Oncology, Beijing Cancer Hospital, 100142 - Beijing/CN [3]Oncology Department, Jinan Central Hospital, jinan/CN [4]Respiratory Medicine Department, Anhui Provincial Hospital, Hefei/CN [5]Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou/CN [6]Oncology Department, Shengjing Hospital of China Medical University, Hua Xiang Branch Hospital, Shenyang/CN [7]Department Of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin/CN [8]Department Of Thoracic Oncology, Sichuan Cancer Hospital & Institute, Chengdu/CN [9]Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN [10]Thoracic Oncology, Hunan Cancer Hospital, Changsha/CN [11]Thoracic Oncology, Fujian Provincial Cancer Hospital, 350014 - Fuzhou/CN [12]Pharmacology Base, The First Hospital of Jilin University, 130021 - Changchun/CN [13]Department Of Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou/CN [14]Thoracic Oncology, West China Hospital, Sichuan University, Chengdu/CN [15]Department Of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang/CN [16]Clinical Development And Regulatory Affairs, CStone Pharmaceuticals (Su Zhou) Co., Ltd, Suzhou/CN
出处：
ISSN：

关键词： NSCLC a phase III trial PD-L1 mAb

基金：
CStone Pharmaceuticals.
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
推荐引用方式(GB/T 7714)：
C. Zhou,Z. Wang,Y. Sun,et al.GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(10):S926-S927.
APA：
C. Zhou,Z. Wang,Y. Sun,L. Cao,Z. Ma...&J. Yang.(2021).GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC.JOURNAL OF THORACIC ONCOLOGY,16,(10)
MLA：
C. Zhou,et al."GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC".JOURNAL OF THORACIC ONCOLOGY 16..10(2021):S926-S927

相关文献

[1]A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC [2]Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial [3]BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201) [4]Nutritional outcomes after radiotherapy target volume reduction for nasopharyngeal cancer: a Phase III trial. [5]Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial [6]Transanal vs laparoscopic total mesorectal excision for rectal cancer: a multicenter randomized phase III clinical trial (TaLaR trial) protocol. [7]A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. [8]GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [9]Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial [10]Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号